Results 51 to 60 of about 44,802 (314)
PROPAFENONE, A NEW EFFECTIVE ANTIARRHYTHMIC DRUG. REPORT OF 2 YEARS CLINICAL EXPERIMENT WITH PROPAFENONE (WITH BRIEF REVIEW OF ARTICLES) [PDF]
Acta Medica Iranica, 1986 Propafenone HCI (p), is a relatively new Class IC antiarrhythmic agent. It has been reported to be superior to conventional antiarrhythmics in the control of supraventricular, ventricular and WPW associated tachyarrhythmias.
IRAJ NAZERY +1 more
doaj +1 more source
Progressive multifaceted approach to the management of geriatric patients with cardiac arrhythmias
Кардиоваскулярная терапия и профилактика, 2020 Aim. To develop a progressive multifaceted approach to the management of geriatric patients with cardiac arrhythmias.Material and methods. The study was carried out in 2 stages.
A. N. Ilnitski +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen +8 more
wiley +1 more source
Propafenone in complex anti-recurrent therapy of persistent atrial fibrillation
Российский кардиологический журнал, 2007 Effectiveness and safety of Class IС antiarrhythmic agent, propafenone (Propanorm, PRO. MED. CS Praha a.s., Czech Republic), was studied inpatients with persistent atrial fibrillation (PAF) after sinus rhythm conversion, during long-term ant-recurrent ...
V. V. Skibitsky +3 more
doaj
Annals of Cardiac Anaesthesia, 2022 A 65-year-old male post-CABG surgery presented with history of ventricular storm refractory to antiarrhythmics and requiring multiple DC shocks. He got posted for VATs bilateral cardiac denervation for sympathetic remodulation.
Gayatri R Sakrikar +3 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Treatment for cardiac arrhythmias in pregnancy: Efficiency and safety
КардиоСоматика, 2013 Pregnancy with its physiological neurohumoral and hemodynamic changes may cause new-onset cardiac arrhythmia or worsen existing arrhythmias. It is important to single out the arrhythmias in pregnant women, which pose no risk for mother or fetus and ...
Yu. A Bunin
doaj
Ventricular Tachycardia in an Elderly Male With Brugada Syndrome
Journal of Investigative Medicine High Impact Case Reports, 2023 We present a case of Brugada syndrome in a 74-year-old patient who presented with urine retention and incidentally found to have non–sustained ventricular tachycardia (NSVT) on electrocardiogram (ECG) and telemetry.
Mohammad Jaber MD +4 more
doaj +1 more source
Pharmaceuticals, 2022 Here, we investigated the reaction of 1,3-dipolar cycloaddition of 1,3-diazido-2-nitro-2- azapropane (DANP) to propargyl alcohol over a copper-based catalyst and identified the optimum reaction conditions that enable the synthesis of 2-nitro-1,3-bis(4,4′-
Elena O. Shestakova +8 more
doaj +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source